Legal barriers are preventing generic drug makers from being able to utilize the Patent Trial and Appeal Board for its intended purpose — to serve as a faster and less cumbersome alternative to district court litigation.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 per month
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Rome, B. N., Lee, C. C. & Kesselheim, A. S. Clin. Pharmacol. Ther. 109, 367–371 (2021).
Rai, A., Vishnubhakat, S., Lemus, J. & Hovenkamp, E. Berkeley Technol. Law J. (in the press).
Dave, C. V., Sinha, M. S., Beall, R. F. & Kesselheim, A. S. Health Aff. (Millwood) 39, 1011–1017 (2020).
RxNorm (NIH NLM, accessed 10 August 2022); https://go.nature.com/3e55x8s
The authors thank B. Sampat and K. Shadlen for helpful comments and A. Kesselheim for input on data sources. They are also grateful to A. Jakubow for assistance with coding and data gathering, and to A. Stewart for excellent research assistant work. This research was supported by a grant from the Arnold Foundation.
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Hovenkamp, E., Lemus, J., Rai, A. et al. Has the PTAB made a difference in drug settlements and generic entry?. Nat Biotechnol 40, 1569–1572 (2022). https://doi.org/10.1038/s41587-022-01526-5